Standard triple therapy for H. pylori now fails roughly 25% of the time as antibiotic resistance rises. Adding 200 mg twice daily of bovine lactoferrin to triple or quadruple therapy boosts eradication rates by 9-12 percentage points across multiple meta-analyses — with no added toxicity.
*Helicobacter pylori* infects roughly half of the global population and causes peptic ulcer disease, chronic gastritis, MALT lymphoma, and a substantial fraction of gastric adenocarcinomas. Treatment has become increasingly difficult: clarithromycin resistance now exceeds 30% in many regions, and standard triple therapy (PPI + clarithromycin + amoxicillin) achieves eradication in only 70–80% of patients.
Bovine lactoferrin has emerged as one of the few well-evidenced adjuncts that meaningfully improves eradication rates. The 2024 meta-analysis pooling 18 RCTs found adding 200 mg twice daily lactoferrin to standard regimens improved eradication by 9–12 percentage points (from ~75% to ~85%) and reduced treatment-related side effects by approximately 30%.
The mechanisms are particularly well-suited to *H. pylori* biology:
*H. pylori* requires iron for growth and uses host transferrin and hemoglobin as iron sources. Lactoferrin's exceptionally high iron affinity (Kd ≈ 10⁻²⁰ M) outcompetes *H. pylori* iron acquisition systems, slowing bacterial growth and enhancing antibiotic susceptibility.
Lactoferricin (the lactoferrin-derived peptide) has direct bactericidal activity against *H. pylori* in vitro at concentrations achievable in the stomach with oral supplementation.
*H. pylori* forms biofilms on the gastric mucosa that protect it from antibiotic penetration. Lactoferrin destabilizes these biofilms by stripping the iron they require for matrix cohesion. This is one of the leading mechanistic explanations for the eradication rate improvement.
Lactoferrin reduces the IL-8 and TNF-α surge driven by *H. pylori* CagA-positive strains, improving gastric mucosal healing during and after eradication.
The trials use different lactoferrin doses (100–400 mg/day) and timings; the most consistent benefit is seen at 200 mg twice daily.
Continue lactoferrin for an additional 14 days after completing antibiotics (28 days total) to support gastric mucosal healing.
The bismuth + lactoferrin combination is particularly synergistic — both target bacterial membrane integrity through different mechanisms.
If first-line therapy fails, second-line regimens (levofloxacin-based or rifabutin-based) achieve only modest eradication rates. Adding lactoferrin to salvage therapy has shown particular value in some series, with 78% eradication vs 65% without the adjunct.
Take lactoferrin at least 2 hours after PPI doses (PPIs can briefly reduce gastric concentrations of any orally administered protein, though the effect on lactoferrin is debated). Take lactoferrin at least 1 hour separated from the antibiotic doses to maximize independent activity at different mucosal sites.
*Lactobacillus reuteri* and *Saccharomyces boulardii* are the best-evidenced probiotics for *H. pylori* adjunct therapy. They are compatible with lactoferrin if separated by 2 hours. The combined approach (antibiotics + lactoferrin + probiotics) has the best meta-analytic eradication rates of any adjunctive strategy.
The lactoferrin adjunct is reasonable for nearly all patients undergoing *H. pylori* eradication, but is particularly worth recommending for:
Lactoferrin alone does not eradicate *H. pylori*. Some early studies tested lactoferrin monotherapy and showed only modest reductions in bacterial load without true eradication. The supplement is an adjunct to antibiotic therapy, not a replacement.
Patients seeking to avoid antibiotics entirely should discuss alternatives with a gastroenterologist; current evidence does not support lactoferrin monotherapy as adequate treatment.
Lactoferrin has no documented interactions with PPIs, clarithromycin, amoxicillin, metronidazole, tetracycline, or bismuth. It does not affect cytochrome P450 enzymes. The safety database during eradication therapy is excellent — the only contraindication is severe cow's milk protein allergy.
How much does lactoferrin actually improve eradication rates? Pooled meta-analysis: from 73.9% to 84.7% (10.8 percentage point improvement). For an individual patient, this means roughly a 1-in-9 chance that adding lactoferrin makes the difference between eradication and failure.
Will lactoferrin reduce my antibiotic side effects? Yes, modestly. Diarrhea, nausea, and dysgeusia rates were lower in lactoferrin arms across multiple trials, likely from gut microbiome protection.
Should I keep taking lactoferrin after eradication is confirmed? Optional. Continuing 200 mg/day for several months post-eradication may support gastric mucosal healing and help prevent reinfection.
Can lactoferrin prevent H. pylori reinfection? Possibly. The mechanisms are plausible. There is no large RCT confirming reinfection prevention, but case series in high-risk populations suggest a protective effect.
What about for confirmed peptic ulcer disease? Lactoferrin during and after eradication may speed ulcer healing through anti-inflammatory and mucosal-protective mechanisms. It is a reasonable adjunct alongside standard PPI ulcer therapy.